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Abstract
 
Soluble foreign antigen usually leads to a transient clonal expansion of antigen-specific T cells
followed by the deletion and/or functional inactivation of the cells. As interleukin (IL)-10 is a
key immunoregulatory cytokine, we questioned whether neutralization of IL-10 during prim-
ing with soluble antigen could prime for a subsequent T helper cell type 1 (Th1) effector recall
response. By using an adoptive transfer model to track the fate of antigen-specific T cell recep-
tor (TCR)-transgenic CD4
 
1
 
 T cells, we show that administration of soluble ovalbumin (OVA)
protein, but not OVA
 
323–339 
 
peptide antigen, together with an anti–IL-10 receptor (R) mAb
led to the enhancement of a Th1 response upon rechallenge. Lipopolysaccharide (LPS) present
in the protein was necessary for priming for Th1 recall responses in the presence of anti–IL-
10R mAb, as removal of LPS abrogated this effect. Moreover, addition of LPS to the peptide
did not itself allow priming for recall Th1 effector responses unless endogenous levels of IL-10
were neutralized with an anti–IL-10R mAb. A significant increase in OVA-specific IgG1 and
IgG2a isotypes was observed when the protein antigen was administered with anti–IL-10R
mAb; however, this was not the case with peptide antigen administered together with anti–IL-
10R and LPS. Our data, showing that LPS receptor signaling and neutralization of endogenous
immunosuppressive cytokines is essential for Th1 priming, has important implications for the
design of relevant vaccines for effective in vivo immunotherapy.
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Introduction
 
Several factors may determine whether encounter of anti-
gen in a primary response will lead to the clonal expansion
of specific antigen receptor–expressing lymphocytes and
their differentiation into specific memory effector cells (for
review see references 1 and 2). Soluble foreign antigen usu-
ally leads to a transient clonal expansion of antigen-specific
T cells, followed by the deletion and/or functional inactiva-
tion of the cells (for review see references 1 and 2). In some
cases, soluble antigen can lead to subsequent unresponsive-
ness to an immunizing regimen of antigen in adjuvant (for
review see references 1 and 2). It has been suggested that
the dose and form of antigen, the route of administration of
antigen, the delivery of appropriate costimulatory signals,
and the genetic background of the host may determine
whether an antigen primes for an appropriate memory ef-
fector response (for review see references 1–3).
Several mechanisms have been proposed to explain the
abortive immune response initiated by soluble antigen, in-
cluding deletion or anergy (for review see references 1 and
2). In addition, soluble antigen does not lead to activation
of the innate immune response to produce inflammatory
mediators as induced by infectious organisms or adjuvants,
such as CFA (containing mycobacteria) or LPS (endotoxin)
required for effective priming of Th1 responses (4, 5). Al-
ternatively, soluble antigen intraperitoneally (3, 6, 7) has
 
been proposed to result in a Th1
 
®
 
Th2 switch, with abro-
gation of cell-mediated immune Th1 responses, character-
ized by CD4
 
1
 
 T cell proliferation, IL-2 and IFN-
 
g
 
 produc-
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tion, and switching to IgG2a. Under such circumstances,
Th2 responses with IL-4 production and IgE remained in-
tact or were elevated (3, 6, 7). However, other reports of
soluble antigen–induced tolerance have not been inter-
preted as a Th1
 
®
 
Th2 switch, as IL-4–producing CD4
 
1
 
 T
cells could not be detected (8). A mechanism for regulation
of organ-specific autoimmune pathology has also been sug-
gested to result from a switch of a cell-mediated Th1-type
response to a Th2 response (9). However, recent studies
suggest that active tolerance to self- and gut antigens may
not be so simple and that other regulatory cells may exist
that produce TGF-
 
b
 
 and/or, in some cases, IL-10 (10–14).
IL-10 inhibits the production of Th1-specific cytokines
by its effects on the APC and downregulates inflammatory
cytokines such as IL-12 (15, 16), as well as the expression
of costimulators (17) and class II MHC (18). Most impor-
tantly, IL-10 has been shown to inhibit the maturation of
dendritic cells (DCs), which are the principle APCs in-
volved in the initiation of an immune response (19). There
is evidence that IL-10 plays an important role in mucosal
immune regulation as well as preventing more generalized
immunopathologies. Mice with a targeted disruption of the
IL-10 gene (IL-10
 
2
 
/
 
2
 
 mice) developed enterocolitis (20)
and showed increased sensitivity to LPS-induced shock
(21). In addition, IL-10
 
2
 
/
 
2 
 
mice showed enhanced disease
as compared with wild-type mice when experimental au-
toimmune encephalomyelitis was induced by MOG
 
35–55 
 
in
CFA (22), suggesting a role for IL-10 in protection from
the development of autoimmunity.
In this study, we investigate whether neutralization of
IL-10 allows exogenous soluble peptide or protein antigens
to prime for Th1 effector responses. We show that neutral-
izing endogenous IL-10 with an anti–IL-10R mAb can
render soluble peptide or protein antigen immunogenic for
Th1 recall responses, provided that there is LPS present to
activate the innate immune response.
 
Materials and Methods
 
Animals.
 
Mice transgenic for the DO11.10 
 
a/b
 
 TCR (23)
on a BALB/c genetic background were identified at age 4–6 wk
by staining peripheral blood leukocytes with the anti-TCR
clonotype-specific mAb KJ1-26, as previously described by Kear-
ney et al. (24). These mice were heterozygous for the TCR 
 
a
 
and 
 
b
 
 transgenes. Mice transgenic for the DO11.10 
 
a/b
 
 TCR
were backcrossed on a RAG-deficient (RAG
 
2
 
/
 
2
 
) BALB/c back-
ground. Female nontransgenic BALB/c mice between 8 and 10
wk old were purchased from Taconic Farms, Inc.
 
Culture Medium, Antigens, Antibodies, and other Reagents.
 
cRPMI 1640 (BioWhittaker) supplemented with 10% FCS (Hy-
clone), 2-ME (0.05 mM; GIBCO BRL), 
 
l
 
-glutamine (1 mM),
penicillin (100 U/ml), streptomycin (100 
 
m
 
g/ml), Hepes buffer
(10 mM), and sodium pyruvate (1 mM) was used as culture me-
dium.
The antigenic OVA peptide (OVA) from chicken ovalbumin
(OVA
 
323–339
 
) was synthesized free of endotoxin (Biosynthesis,
Inc.). OVA was purchased from Calbiochem (28 EU/mg of en-
dotoxin/LPS).
 
Anti–IL-10R mAb was provided by K. Moore (DNAX, Palo
Alto, CA; reference 25), and an isotype-matched control was
supplied by J. Abrams (DNAX). mAbs used for flow cytometric
analysis included anti–mouse CD4–Cy5, 
 
l
 
-selectin–PE (Phar-
Mingen), and anticlonotype mAb for transgenic DO11.10 TCR,
KJ1-26 (26). Additional anticytokine mAbs for immunoassay and
flow cytometry, including anti–mouse IL-10 and IFN-
 
g
 
 reagents,
were purified as previously described (27).
 
Adoptive Transfer and Immunization.
 
The adoptive transfer
was performed as previously described by Kearney et al. (24). In
brief, a single spleen cell suspension from DO11.10 transgenic
mice was injected intravenously into unmanipulated syngeneic
BALB/c recipients such that 4–5 
 
3 
 
10
 
6
 
 KJ1-26
 
1
 
CD4
 
1
 
 T cells
were adoptively transferred. Mice were primed 2 d after adoptive
transfer with either OVA
 
323–339 
 
(7 or 200 
 
m
 
g) or OVA (200 
 
m
 
g or
5 mg) subcutaneously at the base of the tail (similar trends were
obtained with both doses of antigen but results are shown for
higher doses, as higher numbers of antigen-specific CD4
 
1
 
 T cells
were visualized). Mice were rechallenged subcutaneously 12 d af-
ter priming with OVA (100 
 
m
 
g) emulsified in CFA (Difco Labs.).
Mice were analyzed at indicated time points after rechallenge. In
some experiments, mice were injected intraperitoneally with
anti–IL-10R (0.5 mg) mAb (25) weekly throughout the experi-
ments, starting at the day of priming.
 
Preparation of T Cells and APCs.
 
CD4
 
1
 
 T cells were enriched
by positive selection using MiniMACS™ separation columns
(Miltenyi Biotec) to achieve 98% CD4
 
1
 
 T cells. Cells were then
set up in culture at 2 
 
3
 
 10
 
5
 
 per well and restimulated with
OVA
 
323–339 
 
(1 
 
m
 
M) and irradiated syngeneic splenic APCs (5 
 
3
 
10
 
5
 
 per well). Supernatants were collected at 24 h for the mea-
surement of IL-2 and at 48 h for the measurement of IFN-
 
g
 
, IL-4,
and IL-10 by immunoassay (27).
 
Cytokine Assays.
 
IFN-
 
g
 
 was detected using a two-site sand-
wich ELISA, with a lower limit of sensitivity of 100 pg/ml. The
ELISA for IL-2 has been described previously (27), with a limit of
sensitivity of 195 pg/ml.
 
OVA-specific Serum Isotype ELISAs.
 
For analysis of OVA-
specific IgG1 and IgG2a, 96-well plates (Fisher Scientific) were
coated with whole OVA (Sigma-Aldrich), 10 
 
m
 
g/ml in PBS.
Plates were blocked with 20% FCS, and serum samples were
added at appropriate dilutions. Samples were developed by se-
quential incubation with biotinylated IgG1 or IgG2a isotype–
specific mAb (PharMingen), streptavidin–horseradish peroxidase
(Caltag Labs.), and substrate (Kirkegaard & Perry Laboratories,
Inc.). OVA-specific IgE and IgA isotype titers were determined
as previously described (28). Plates were read at 450 nm and ana-
lyzed based on OVA-specific isotype standards. Data shown are
OVA-specific isotype titers in nanograms per milliliter.
 
Removal of LPS.
 
To deplete the LPS (otherwise known as
endotoxin) from the OVA protein antigen preparation (activity
detected by limulus amebocyte assay; BioWhittaker), OVA at 10
mg/ml was adsorbed on a Detoxi-Gel™ Endotoxin Removing
Gel (Pierce Chemical Co.) according to the manufacturer’s in-
structions to reduce endotoxin levels to below the level of 5 EU
per 5 mg of protein.
 
Results and Discussion
 
Neutralization of IL-10 during Priming with Soluble OVA
Protein but Not OVA
 
323–339 
 
Peptide Antigen Leads to the De-
velopment of a Th1 Effector Recall Response.
 
To determine
whether neutralization of IL-10 could allow soluble pep- 
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tide and protein antigen to prime for a Th1 effector im-
mune response, BALB/c mice, which had been previously
transferred with OVA-specific CD4
 
1
 
 T cells (KJ1-26
 
1
 
CD4
 
1
 
) from DO11.10 mice, were primed subcutaneously
with soluble OVA
 
323–339 
 
peptide or protein in the presence
or absence of an IL-10R mAb (25). Mice were then re-
challenged using OVA protein in CFA, and purified CD4
 
1
 
T cells from lymph nodes were analyzed for their ability to
produce enhanced levels of IFN-
 
g 
 
as a result of appropriate
priming. As previously shown (24), CD4
 
1
 
 T cells obtained
from mice that had received soluble OVA
 
323–339 
 
before
challenge produced significantly less IL-2 in vitro in re-
sponse to OVA
 
323–339 
 
presented by irradiated APCs than
CD4
 
1
 
 T cells obtained from mice that had received PBS
(Fig. 1, top). This correlated with significantly reduced
numbers of antigen-specific CD4
 
1
 
 T cells and reduced
[
 
3
 
H]thymidine incorporation in vitro in response to specific
antigen (data not shown). Immunizing mice with OVA
 
323–339
 
peptide antigen in the presence of an anti–IL-10R mAb
did not enhance the production of IL-2 (Fig. 1) nor the
number of antigen-specific T cells and their [
 
3
 
H]thymidine
incorporation (data not shown). Treatment with soluble
OVA protein antigen before rechallenge with OVA in
CFA led to a small but reproducible decrease in IL-2 pro-
duction (
 
,
 
50% in more than three experiments; Fig. 1,
top). A small reduction in the number of antigen-specific
CD4
 
1
 
 T cells was observed and reduced [
 
3
 
H]thymidine in-
corporation in vitro in response to specific antigen (data
not shown). The presence of a mAb directed against the
IL-10R during priming with soluble protein (in contrast to
peptide) antigen enhanced the levels of IL-2 produced by
CD4
 
1
 
 T cells almost to the level produced by CD4
 
1
 
 T
cells from mice that were pretreated with PBS before the
OVA in CFA challenge. This increase could be accounted
for completely by an increase in KJ1-26
 
1
 
CD4
 
1
 
 T cells, as
on a per cell basis, IL-2 levels were identical in the presence
or absence of anti–IL-10R mAb (Fig. 1, bottom).
CD4
 
1
 
 T cells from mice that had previously received
soluble protein or peptide antigen produced similar or
lower levels of IFN-
 
g
 
 upon restimulation in vitro relative
to the levels obtained from unprimed mice that had only
been given the OVA in CFA challenge (Fig. 1). This
showed that soluble antigen did not prime for an effector
Th1-type response and in some instances (not shown) actu-
ally led to suppressed levels of IFN-
 
g
 
 production upon
rechallenge with CFA plus OVA. Addition of the anti–IL-
10R mAb could not convert the soluble OVA
 
323–339 
 
pep-
tide into a priming regimen for a Th1 response and the
production of IFN-
 
g
 
 (Fig. 1), even when the peptide was
administered repeatedly to compensate for its shorter half-
life in vivo (data not shown). In contrast, simultaneous ad-
ministration of the anti–IL-10R mAb with the soluble
OVA protein led to effective priming for a Th1 effector re-
sponse, with highly elevated and prolonged levels of IFN-
 
g
 
production (Fig. 1, top). This increase not only resulted
from an increased number of antigen-specific CD4
 
1
 
 T cells
producing IFN-
 
g
 
 but also reflected an increase in the
amount of IFN-
 
g
 
 produced per antigen-specific CD4
 
1
 
 T
cell (Fig. 1, bottom). A higher level of fluorescence inten-
sity for intracellular IFN-
 
g
 
 production in a greater percent-
age of the cells as shown by flow cytometry was also ob-
served (data not shown). We have previously shown that
this increase in fluorescence intensity for cytokine staining
correlates with maximal IFN-
 
g
 
 production from commit-
ted Th1 cells stimulated appropriately (O’Garra, A., un-
published data). Early production of IL-10 during the pri-
Figure 1. Treatment of OVA-primed mice with
anti–IL-10R mAb before rechallenge potentiates the
production of IFN-g. CD41 T cells were purified
from the draining lymph nodes of mice primed and
rechallenged as indicated in Materials and Methods
and stimulated in vitro with OVA323–339 and APCs.
Supernatants were harvested after 24 (IL-2) or 48 h
(IFN-g) of culture. 
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mary response to protein antigen (data not shown) could
possibly explain the rapid downregulation of IFN-
 
g
 
 by the
inhibitory effects of IL-10 on APCs (15) and may account
for the poor ability of soluble protein antigen to prime for
subsequent effector immune responses.
 
Anti–IL-10R mAb Is an Adjuvant for Priming Th1 Effector
Recall Responses Only in the Presence of LPS.
 
As the OVA
protein preparation but not the OVA
 
323–339 
 
peptide prepa-
ration contains low amounts of LPS (28 EU/mg), we de-
termined if LPS together with the anti–IL-10R mAb was
required for the OVA protein to prime for a Th1 effector
recall response. To investigate this, we first purified the
LPS-free OVA protein using a Detoxi-Gel™ Endotoxin
Removing Gel to 
 
,
 
5 EU/5 mg and then compared its
ability to prime for a subsequent Th1 recall response with
the original OVA protein preparation. As shown in Fig. 2,
when the contaminating LPS was removed from the OVA
protein (referred to as 
 
*
 
OVA), anti–IL-10R mAb had little
effect on priming for a Th1 recall response, in contrast to
its effects with the original OVA preparation. Furthermore,
addition of similar amounts of LPS (140 EU [14 ng]) to the
OVA
 
323–339 
 
peptide resulted in successful priming for a Th1
recall response only in the presence of the anti–IL-10R
mAb. Thus, triggering of the innate immune response by
low levels of LPS is not sufficient to allow soluble peptide
or protein antigens to prime for Th1 recall responses unless
the suppressive effect of IL-10 is neutralized. Additionally,
these data show unequivocally that the ability of IL-10 to
regulate the immune response only comes into play when
there is simultaneous activation of the innate immune re-
sponse.
 
Anti–IL-10R mAb Plus LPS Enhances Antigen-specific
IgG1 and IgG2a Levels to Protein but Not Peptide Antigen.
 
In addition to the enhanced production of IFN-
 
g
 
 by
CD4
 
1
 
 T cells, soluble OVA protein administered together
with anti–IL-10R mAb also led to a significant enhance-
ment of OVA-specific IgG1 and IgG2a antibodies upon re-
challenge (Fig. 3). This enhancement was abrogated upon
removal of LPS from the protein antigen (data not shown).
Soluble OVA
 
323–339 
 
peptide, when delivered with or with-
out anti–IL-10R mAbs, did not induce OVA-specific IgG
antibody responses. Furthermore, although addition of
similar amounts of LPS to the OVA
 
323–339 peptide resulted
in successful priming for a Th1 recall response in the pres-
ence of the anti–IL-10R mAb, this did not lead to priming
for IgG2a responses (data not shown), in keeping with a re-
quirement for cross-linking of the antigen for generation of
antibody production from B cells.
The effects of neutralizing IL-10 may result indirectly
from enhancement of CD41 T cell help by releasing inhi-
bition of APC function in a primary immune response (15,
16). A dominant property of IL-10 is its ability to down-
regulate the APC function of macrophages and/or DCs
(15). These effects include the expression of costimulators
such as CD80 and CD86 (17), the trafficking of peptide-
bearing class II MHC molecules (18), and the inhibition of
production of inflammatory mediators such as IL-12,
which are required for the development and maintenance
of Th1 responses (16, 29). DCs, the principal APCs in-
Figure 2. Neutralization of IL-10 allows priming for Th1 recall re-
sponses by soluble protein or peptide antigen only when low levels of
LPS are present. CD41 T cells were purified from the draining lymph
nodes of mice primed with OVA protein, OVA protein that had been
purified as free of LPS (*OVA), or OVA323–339 peptide antigen in the
presence or absence of LPS (140 EU [14 ng]) plus or minus anti–IL-10R
mAbs as shown. Mice were then rechallenged with OVA and CFA as in-
dicated in Materials and Methods and stimulated in vitro with OVA323–339
and APCs. Supernatants were harvested after 24 (IL-2) or 48 h (IFN-g) of
culture. Results were reproducible in greater than three experiments.
Figure 3. Anti–IL-10R mAb
plus LPS enhances antigen-spe-
cific IgG1 and IgG2a levels with
protein and not peptide antigen.
Mice were primed and rechal-
lenged as indicated in Materials
and Methods. Serum was col-
lected 7 d after rechallenge with
OVA in CFA. The average con-
centration in nanograms per mil-
liliter for each isotype is indi-
cated in parentheses. Each
symbol represents data from an
individual mouse. Results were
reproducible in greater than
three experiments.1533 Castro et al. Brief Definitive Report
volved in the initiation of an immune response, capture
foreign antigens encountered in peripheral tissues, process
the antigens into peptides bound to MHC molecules, and
migrate to lymphoid organs for presentation of the MHC–
peptide complexes to lymphocytes (19). Furthermore, on
the one hand, proinflammatory agents such as LPS are
strong inducers of DC maturation (30, 31), whereas IL-10
inhibits DC maturation (for review see reference 19).
Thus, it is likely that a delicate balance between proinflam-
matory factors and IL-10 is critical in the tight regulation of
the transition of resting/immature DCs to mature DCs and
hence the initiation of an immune response. It has been re-
cently reported that immature DCs sequester intact anti-
gens in lysosomes and that neither peptides nor proteins are
converted to peptide–MHC class II complexes until a
maturation stimulus such as LPS is received (32, 33), a
component of Gram-negative bacterial pathogens (34).
Furthermore, it has also been shown that LPS promotes ac-
cumulation of antigen-bearing DCs in the T cell areas of
lymphoid tissue (35). Thus, it is likely that IL-10 can act as
a limiting factor at this stage to regulate the magnitude of
an immune response by inhibiting the maturation of DCs,
as well as possibly inhibiting the migration of initiating
APCs. The results in this study may have implications for
the breakdown of tolerance to autoantigens, which has
been suggested to be initiated by infection. This may also
require a genetic predisposition of the host for a defect in
the production or signaling capacity of immunoregulatory
molecules such as IL-10. This would result in a lower
threshold of reactivity of autoreactive T cells in the context
of activation of inflammatory molecules of the innate im-
mune response, as exemplified by the findings of Bettelli et
al. (22) in the induction of EAE.
In summary, we show that anti–IL-10R can render solu-
ble peptide or protein antigen immunogenic for subse-
quent Th1 recall responses, provided that there is a signal
such as LPS present to activate the innate immune re-
sponse. These findings have important implications for the
design of relevant vaccines for in vivo immunotherapy and
suggest that, in addition to triggering T cells through the
TCR via specific antigen, this will require signaling
through Toll receptors as well as neutralization of endoge-
nous suppressive molecules such as IL-10.
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